We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)


FY23 results point to strong financials and fundamentals

Lighthouse | 29 February 2024

Redx Pharma

Ready to ROCK as RXC008 enters the clinic

Update | 28 February 2024


Fruquintinib clinical and commercial updates

Lighthouse | 12 February 2024

Redx Pharma

Up to $870m KRAS deal marks third Jazz collaboration

Lighthouse | 07 February 2024

Futura Medical

Eroxon continues to build, further new launches expected

Lighthouse | 06 February 2024

Arecor Therapeutics

New deals and first royalties to aid growth; key data H124

Lighthouse | 01 February 2024


Heading into important 2024 clinical catalysts

Update | 31 January 2024


Building content to drive widespread adoption

Update | 30 January 2024

Arecor Therapeutics

Sanofi deal for INBRX-101 validates Arestat technology

Lighthouse | 24 January 2024

Redx Pharma

Anticipating clinical momentum and catalysts in 2024

Update | 19 December 2023
1 2 3 4 5 6 7 8 9 10 >
399 results found.